Microarray: An instrument for cancer surgeons of the future?: Surgical science

ANZ Journal of Surgery

Volumn 80, Issue 7-8, 2010, Pages 531-536

  Broadhead, Matthew L ^a   Clark, Jonathan C M ^a   Dass, Crispin R ^a   Choong, Peter F M ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Breast; Microarray; Osteosarcoma; Pancreas; Prostate

Indexed keywords

TUMOR MARKER;

ARTICLE; DNA MICROARRAY; FORECASTING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METHODOLOGY; NEOPLASM; PREDICTIVE VALUE;

FORECASTING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955385394     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2010.05379.x     Document Type: Article

References (38)

1. Casey DK. Genomics and its impact on science and society: the human genome project and beyond Cited 2008.] Available from URL: http://www.ornl.gov/ sci/techresources/Human-Genome/publicat/primer2001/index.shtml
2. Alberts A, Johnson J, Lewis J, Raff M, Roberts K, Walter P (eds). Molecular biology of the cell, 5th edn.
3. Thomas DM, Fleming NI, Holloway AJ, Bowtell DD. Molecular medicine: a clinician's primer on microarrays. Intern. Med. J. 2004 34 : 565 9.
4. Yap G. Affymetrix, Inc. Pharmacogenomics 2002 3 : 709 11.
5. Bridgewater J, van Laar R, Floore A, Van TVL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br. J. Cancer 2008 98 : 1425 30.
6. Giordano TJ, Shedden KA, Schwartz DR et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am. J. Pathol. 2001 159 : 1231 8.
7. Ramaswamy S, Tamayo P, Rifkin R et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. U. S. A. 2001 98 : 15149 54.
8. Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001 61 : 7388 93.
9. Buckhaults P, Zhang Z, Chen YC et al. Identifying tumor origin using a gene expression-based classification map. Cancer Res. 2003 63 : 4144 9.
10. Shedden KA, Taylor JM, Giordano TJ et al. Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am. J. Pathol. 2003 163 : 1985 95.
11. Bloom G, Yang IV, Boulware D et al. Multi-platform, multi-site, microarray-based human tumor classification. Am. J. Pathol. 2004 164 : 9 16.
12. Tothill RW, Kowalczyk A, Rischin D et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 2005 65 : 4031 40.
13. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat. Rev. 2009 35 : 221 7.
14. Kumar V, Abbas A, Fausto N (eds). Robbins and Cotran pathologic basis of disease, 7th edn.
15. Lexe G, Monaco J, Doyle S et al. Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging. Exp. Biol. Med. (Maywood) 2009 234 : 860 79.
16. Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev. Anticancer Ther. 2006 6 : 225 37.
17. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J. Natl. Cancer Inst. 1991 83 : 154 5.
18. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 415 : 530 6.
19. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002 347 : 1999 2009.
20. Mook S, Schmidt MK, Viale G et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. 2009 116 : 295 302.
21. Albiges-Sauvin L, Levy A, Massard C, Fizazi K. Prognosis and predictive factors in prostate cancer. Bull. Cancer 2009 96 : 439 49.
22. Ohori M. Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis. Gan To Kagaku Ryoho 2009 36 : 6 10.
23. Grubb RL, Deng J, Pinto PA et al. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J. Proteome Res. 2009 8 : 3044 54.
24. Jhavar S, Bartlett J, Kovacs G et al. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis. 2009 12 : 143 7.
25. Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 2009 69 : 1119 27.
26. Akada M, Crnogorac-Jurcevic T, Lattimore S et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin. Cancer Res. 2005 11 : 3094 101.
27. Erkan M, Kleeff J, Esposito I et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005 24 : 4421 32.
28. Mahon PC, Baril P, Bhakta V et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 2007 67 : 6786 95.
29. Zhao Y-P, Chen G, Feng B, Zhang T-P, Ma E-L, Wu Y-D. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer. Chin Med. J. (Engl) 2007 120 : 1743 52.
30. Mintz MB, Sowers R, Brown KM et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005 65 : 1748 54.
31. Walters DK, Steinmann P, Langsam B, Schmutz S, Born W, Fuchs B. Identification of potential chemoresistance genes in osteosarcoma. Anticancer Res. 2008 28 : 673 9.
32. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br. J. Cancer 2001 84 : 951 8.
33. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001 12 : 459 65.
34. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003 33 : 216 28.
35. Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther. 2007 6 : 3263 70.
36. Sooriakumaran P, Henderson A, Denham P, Langley SE. A novel method of obtaining prostate tissue for gene expression profiling. Int. J. Surg. Pathol. 2009 17 : 238 43.
37. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer 2007 7 : 545 53.
38. Tebbit CL, Zhai J, Untch BR et al. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res. Treat. 2009 118 : 635 43.